Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Arxx Therapeutics AS (Norway)
Homepage:
callunapharma.com
Alternate names:
Arxx Therapeutics,
Arxx Therapeutics AS
ROR:
04ezasc10
OpenAlex ID:
I4405267804
Works
15
Awards
1
Incidence, Prevalence, and Mortality of Heart Failure: A Nationwide Registry Study from 2013 to 2016
2020
·
Kristina Malene Ødegaard*
, Jonas Hallén
, et al.
·
ESC Heart Failure
·
45
PDF
Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020
2022
·
Kristina Malene Ødegaard
, Sandre Svatun Lirhus
, et al.
·
ESC Heart Failure
·
42
PDF
Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin
2023
·
Thuong Trinh‐Minh
, Andrea‐Hermina Györfi
, et al.
·
Arthritis & Rheumatology
·
30
Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis
2023
·
Christopher P Denton
, Shiwen Xu
, et al.
·
Annals of the Rheumatic Diseases
·
16
PDF
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry
2021
·
Uwe Zeymer
, Andrew L Clark
, et al.
·
European Heart Journal - Quality of Care and Clinical Outcomes
·
15
A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates
2022
·
Kristina Malene Ødegaard
, Sandre Svatun Lirhus
, et al.
·
BMC Cardiovascular Disorders
·
14
PDF
S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin
2023
·
Xiao Švec
, Hana Štorkánová
, et al.
·
Rheumatology
·
12
PDF
Outcomes with Sacubitril/Valsartan in Outpatients with Heart Failure and Reduced Ejection Fraction: The ARIADNE Registry
2022
·
Aldo P. Maggioni
, Andrew L. Clark
, et al.
·
ESC Heart Failure
·
8
PDF
A nationwide registry study on heart failure in Norway from 2008–2018: variations in lookback period affect incidence estimates
2021
·
K.M Odegaard
, S Lirhus
, et al.
·
European Heart Journal
·
1
PDF
Op0245 Anti-s100a4 Monoclonal Antibody Treatment Ameliorates Skin Fibrosis in Inflammatory and Non-inflammatory Pre-clinical Models of Systemic Sclerosis
2021
·
M. Tomčík
, T. Trinh-Minh
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Ab1144 the Role of Systemic S100a4 Levels in Scleroderma as a Predictor of Treatment Response and Early Progression
2024
·
H. Štorkánová
, L. Andres Cerezo
, et al.
·
Annals of the Rheumatic Diseases
Pos0146 Biosamples From Vedoss Patients Show Classic Pathological Signs of Scleroderma:opportunity for a Biological Diagnosis of Disease
2023
·
R. Ross
, E. Clarke
, et al.
·
Annals of the Rheumatic Diseases
PDF
POS0147 αVβ3 INTEGRIN AS A LINKER BETWEEN FIBROSIS AND THYROID HORMONES CROSSTALK
2023
·
S. Tartakover Matalon
, M. Kohon
, et al.
·
Annals of the Rheumatic Diseases
PDF
Pos0145 Clinical and Pathogenic Significance of S100a4 Overexpression in Systemic Sclerosis
2023
·
V. Ong
, X. Shiwen
, et al.
·
Annals of the Rheumatic Diseases
PDF
PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study
2021
·
FD Richard Hobbs
, Rizwan I Hussain
, et al.
·
Open Heart
PDF
Show more works
View as search
Works count:
15
Citation count:
317
Year
Topic
Type
